Skip to main content

Advertisement

Table 3 BEDiso converted to clinically applicable dose fractionation schedules to achieve at least 90% local control at 2 years of CRC metastases

From: The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases

Tumor location No prior Chemo Prior Chemo
Lung 99 ± 15 Gy10 BEDiso 3 × 9 Gy @ 65% 211 ± 19 Gy10 BEDiso 3 × 15 Gy @ 65%
8 × 5 Gy @ 65% 5 × 10.5 Gy @ 65%
Liver 187 ± 19 Gy10 BEDiso 3 × 14 Gy @ 65% 300 ± 39 Gy10 BEDiso 3 × 18 Gy @ 65%
5 × 10 Gy @ 65% 5 × 13 Gy @ 65%